Blog Index
The journal that this archive was targeting has been deleted. Please update your configuration.

Welcome to Inform Genomics, Inc.

Inform Genomics, Inc, is a company that utilizes a proprietary analytic platform to develop genomic-based, precision medicine products.  Our product candidates are designed to predict, with a high degree of precision and accuracy, clinically important outcomes that assist physicians and their patients in making individualized medical decisions.

Our current focus is in oncology supportive care, with 2 product candidates in development.  Each is designed to accurately predict which patients are at high risk for developing common chemotherapy-related side effects before cancer treatment begins.  These product candidates have the potential to create a new standard of care in today’s oncology practice for the benefit of patients, providers, and payers alike.

Patients could successfully complete their planned course of therapy with fewer or less severe side effects—side effects that might have delayed or even stopped their treatment plan. Physicians stand to benefit because they will be provided actionable information to tailor a patient’s chemotherapy regimen and to plan supportive care strategies in advance of treatment. Payers could realize the economic benefits of reducing the high cost of managing chemotherapy-related side effects in both the short- and long-term.

The US market opportunity for our lead products in cancer supportive care exceeds $2 billion annually.